2-叔丁氧基-5-溴吡啶 | 850495-91-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-叔丁氧基-5-溴吡啶
• 英文名称: 2-tert-butoxy-5-bromopyridine
• 英文别名: 5-bromo-2-(tert-butoxy)pyridine；5-bromo-2-(1,1-dimethylethoxy)pyridine；2-(tBuO)-5-Br-pyridine；5-bromo-2-[(2-methylpropan-2-yl)oxy]pyridine
• CAS: 850495-91-9
• 化学式: C₉H₁₂BrNO
• mdl: MFCD08689444
• 分子量: 230.104
• InChiKey: RJSAAFGYJWKOJU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.444
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  2-叔丁氧基-5-溴吡啶 在 copper(l) iodide 、 potassium carbonate 、 (1R,2R)-(-)-N,N'-二甲基-1,2-环己二胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 24.0h， 生成 1-(1-(6-tert-butoxypyridin-3-yl)-1,6-dihydro-6-oxopyridin-3-yl)-1H-pyridin-2-one
  参考文献：
  名称：

  An improved Ullmann–Ukita–Buchwald–Li conditions for CuI-catalyzed coupling reaction of 2-pyridones with aryl halides

  摘要：

  An effective CuI-trans-N,N'-dimethylcyclohexane-1,2-diamine (DMCDA)-K2CO3-cataIyzed coupling reaction of 2-pyridones with aryl halides is described. Under our conditions, DMCDA was found to be an effective catalyst that facilitates the coupling reactions even in toluene, a common industrial solvent. In addition, 3-bromopyridine could also be coupled effectively under these conditions, indicating that the catalytic reactivity of this system is high. The reaction could be applied for polymer modification and iterative oligo-pyridone synthesis. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2005.01.063
• 作为产物：
  描述：

  2,5-二溴吡啶 、 sodium t-butanolate 以 甲苯 为溶剂， 反应 2.5h， 以56%的产率得到2-叔丁氧基-5-溴吡啶
  参考文献：
  名称：

  An improved Ullmann–Ukita–Buchwald–Li conditions for CuI-catalyzed coupling reaction of 2-pyridones with aryl halides

  摘要：

  An effective CuI-trans-N,N'-dimethylcyclohexane-1,2-diamine (DMCDA)-K2CO3-cataIyzed coupling reaction of 2-pyridones with aryl halides is described. Under our conditions, DMCDA was found to be an effective catalyst that facilitates the coupling reactions even in toluene, a common industrial solvent. In addition, 3-bromopyridine could also be coupled effectively under these conditions, indicating that the catalytic reactivity of this system is high. The reaction could be applied for polymer modification and iterative oligo-pyridone synthesis. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2005.01.063

文献信息

• [EN] TANK-BINDING KINASE INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS DE KINASES SE LIANT À TANK
  申请人：GILEAD SCIENCES INC

  公开号：WO2015187684A1

  公开（公告）日：2015-12-10

  Compounds having the following formula (I) and methods of their use and preparation are disclosed:

  揭示了具有以下化学式（I）的化合物及其使用和制备方法。
• Development of a Two-Step Route to 3-PBC and βCCt, Two Agents Active against Alcohol Self-Administration in Rodent and Primate Models
  作者：Ojas A. Namjoshi、Angelica Gryboski、German O. Fonseca、Michael L. Van Linn、Zhi-jian Wang、Jeffrey R. Deschamps、James M. Cook

  DOI：10.1021/jo200425m

  日期：2011.6.3

  agents active against alcohol self-administration, a two-step route was developed. This process involves a palladium-catalyzed Buchwald–Hartwig coupling and an intramolecular Heck reaction. This two-step route provides rapid access to multigram quantities of 3-PBC (1) and βCCt (2), as well as analogues for studies of alcohol self-administration. The overall yield of 3-PBC (1) was improved from 8% to 50%

  为了获得 3-丙氧基-β-咔啉盐酸盐 (3-PBC·HCl) ( 1·HCl ) 和 β-咔啉-3-羧酸-叔丁酯 (βCCt) ( 2 )，这些潜在的抗酒精临床药物自我管理，制定了一个两步路线。该过程涉及钯催化的 Buchwald-Hartwig 偶联和分子内 Heck 反应。这种两步法可以快速获得数克数量的 3-PBC ( 1 ) 和 βCCt ( 2 )，以及用于酒精自我管理研究的类似物。通过这条路线，3-PBC( 1 )的总产率从8%提高到50%。
• Synthesis and Evaluation of 2,5-Linked Alternating Pyridine−Thiophene Oligomers
  作者：Silvia V. Rocha、Nathaniel S. Finney

  DOI：10.1021/ol1007907

  日期：2010.6.4

  The first iterative access to alternating 2,5-linked pyridine−thiophene (Py−Th) oligomers is presented. These oligomers exhibit strong absorption and emission, even in the solid state (picture of the longest oligomer, above). Protonation leads to large red shifts in emission and, unlike most known thiophene-containing oligomers, they are readily reduced but not oxidized. These species represent a promising

  首次迭代访问交替的2，5-连接的吡啶-噻吩（Py-Th）低聚物。这些低聚物即使在固态下也表现出较强的吸收和发射（上面最长的低聚物的图片）。质子化导致发射的大红移，并且与大多数已知的含噻吩的低聚物不同，质子化很容易被还原但不会被氧化。这些物种代表了有前途的新型材料，有待进一步研究和潜在应用。
• Oligopyridones: preparation and their folding behavior in polar aprotic solvents
  作者：Chih-Kai Liang、Po-Shih Wang、Man-kit Leung

  DOI：10.1016/j.tet.2008.12.024

  日期：2009.2

  The oligomerization of 5-bromo-2-hydroxypyridine through a CuI catalyzed one-pot condensation tactics was developed. A series of oligopyridones, from dipyridione to penta-pyridone, were therefore synthesized via the CuI-promoted C–N coupling reactions. The oligopyridones favor to have folded conformations in polar aprotic solvents. These were confirmed by using 1H NMR, NOESY, and 1D-NOE experiments

  通过CuI催化的一锅缩合策略，开发了5-溴-2-羟基吡啶的低聚反应。因此，通过CuI促进的C–N偶联反应合成了从吡啶酮到五吡啶酮的一系列低聚吡啶酮。寡吡啶酮倾向于在极性非质子溶剂中具有折叠构象。这些通过使用1 H NMR，NOESY和1D-NOE实验得到证实。
• GUANIDINE COMPOUND
  申请人：Astellas Pharma Inc.

  公开号：US20130143860A1

  公开（公告）日：2013-06-06

  [Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that the compound or a salt thereof of the present invention exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. In addition, the present invention relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound or a salt thereof of the present invention, and an excipient.

  [问题]本发明提供一种化合物，用作药物组合物的活性成分，特别是用于预防和/或治疗与VAP-1相关的疾病的药物组合物。 [解决方法]本发明人对具有VAP-1抑制活性的化合物进行了深入研究，结果发现本发明的化合物或其盐表现出优异的VAP-1抑制活性，可用于预防和/或治疗与VAP-1相关的疾病，特别是糖尿病肾病或糖尿病黄斑水肿，从而完成了本发明。此外，本发明涉及一种药物组合物，特别是用于预防和/或治疗与VAP-1相关的疾病的药物组合物，其包括本发明的化合物或其盐和赋形剂。